Imaging agent developer FluoroPharma has begun phase I clinical trials for a myocardial perfusion imaging (MPI) tracer for PET imaging, according to its parent company, QuantRx Biomedical of Doylestown, PA.
The trial is a single-center, open-label study that will evaluate safety, distribution, and dosimetry of the tracer, BFPET, for MPI imaging in healthy subjects. If successful, BFPET will improve coronary artery disease diagnosis and follow-up, and increase PET's utility, according to Boston-based FluoroPharma.
Related Reading
Boston Life Sciences ends FluoroPharma deal, July 27, 2005
Copyright © 2008 AuntMinnie.com
